Bafna Pharmaceuticals Limited AI Stock Analysis
Want to see IN:BAFNAPH full AI Analyst Report?
Bafna Pharmaceuticals Limited (BAFNAPH) AI Stock Analysis
Bafna Pharmaceuticals Limited
(NSE:BAFNAPH)
The overall score is heavily pressured by extremely poor technical and valuation metrics. The stock is deeply overbought with an RSI of 86.9 and carries an unsustainably high P/E ratio of 119.76, both scoring at the minimum. These factors overshadow the company's solid balance sheet and moderate financial performance, which is itself strained by declining margins and negative free cash flow. The primary risk is a potential sharp correction from overbought levels on an already overvalued stock.
Bafna Pharmaceuticals Limited (BAFNAPH) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 11.36B
- Dividend Yield
- ―
- Average Volume (3M)
- 6,324
- Price to Earnings (P/E)
- 96.8
- Beta (1Y)
- 0.58
- Revenue Growth
- 8.74%
- EPS Growth
- 31.20%
- Country
- India
- Employees
- 339
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Bafna Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries....
Bafna Pharmaceuticals Limited Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is strong (Score 78) with low leverage and growing equity. However, the income statement (Score 48) shows significant margin compression, and the cash flow statement (Score 42) reveals persistent negative free cash flow due to heavy capex. The overall profile is weighed down by profitability and cash burn concerns despite a solid foundation.
Income Statement
48NeutralBalance Sheet
78PositiveCash Flow
42Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.44B | 1.51B | 1.46B | 1.52B | 1.15B | 851.40M |
| Gross Profit | 329.05M | 201.42M | 168.77M | 452.15M | 175.56M | 137.18M |
| EBITDA | 166.13M | 207.04M | 117.73M | 146.34M | 189.88M | 112.34M |
| Net Income | 77.86M | 111.00M | 41.52M | 73.48M | 113.38M | 52.16M |
Balance Sheet | ||||||
| Total Assets | 0 | 1.76B | 1.53B | 1.48B | 1.30B | 901.45M |
| Cash, Cash Equivalents and Short-Term Investments | 20.25M | 20.25M | 34.33M | 13.96M | 78.09M | 194.00K |
| Total Debt | 0 | 374.33M | 281.99M | 243.89M | 229.24M | 110.59M |
| Total Liabilities | -961.50M | 793.83M | 682.73M | 668.43M | 561.29M | 281.81M |
| Stockholders Equity | 961.50M | 961.50M | 848.07M | 808.39M | 734.55M | 619.64M |
Cash Flow | ||||||
| Free Cash Flow | -71.04M | -130.76M | -23.31M | -60.93M | -32.66M | 21.87M |
| Operating Cash Flow | 93.13M | 118.27M | 195.29M | 94.85M | 49.52M | 97.28M |
| Investing Cash Flow | -149.13M | -224.69M | -213.02M | -150.54M | -74.93M | -65.44M |
| Financing Cash Flow | 24.23M | 92.35M | 38.09M | -8.45M | 101.77M | -48.15M |
Bafna Pharmaceuticals Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAFNAPH, the sentiment is Positive. The current price of 477.00 is above the 20-day moving average (MA) of 461.90, above the 50-day MA of 402.28, and above the 200-day MA of 228.10, indicating a bullish trend. The MACD of 21.04 indicates Positive momentum. The RSI at 65.45 is Neutral, neither overbought nor oversold. The STOCH value of 68.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BAFNAPH.
Bafna Pharmaceuticals Limited Peers Comparison
Overall Rating
IN:SUPRIYA66Neutral
IN:KILITCH65Neutral
IN:SANOFI65Neutral
IN:HIKAL57Neutral
IN:WOCKPHARMA57Neutral
IN:BAFNAPH46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 66Neutral | INR 49.48B | 27.93 | ― | 0.16% | 23.00% | -2.84% | |
| 65Neutral | INR 8.07B | 32.97 | ― | ― | 13.87% | -17.80% | |
| 65Neutral | INR 74.32B | 20.42 | ― | 3.81% | -5.74% | 2.30% | |
| 57Neutral | INR 27.54B | -557.88 | ― | 0.27% | 8.93% | -149.51% | |
| 57Neutral | INR 329.37B | 80.36 | ― | ― | 25.70% | ― | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 46Neutral | INR 11.36B | 96.79 | ― | ― | 8.74% | 31.20% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:BAFNAPH | Bafna Pharmaceuticals Limited | 477.00 | 306.15 | 179.19% | |
| IN:HIKAL | Hikal Limited | 223.35 | -4.55 | -2.00% | |
| IN:KILITCH | Kilitch Drugs (India) Limited | 230.90 | 49.75 | 27.46% | |
| IN:SANOFI | Sanofi India Limited | 3231.65 | -1177.66 | -26.71% | |
| IN:SUPRIYA | Supriya Lifescience Limited | 614.85 | -156.38 | -20.28% | |
| IN:WOCKPHARMA | Wockhardt Limited | 2027.10 | 702.20 | 53.00% |
Bafna Pharmaceuticals Limited Corporate Events
Bafna Pharmaceuticals Approves Unaudited Results for Quarter and Half Year Ended September 2026
Bafna Pharmaceuticals Limited manufactures pharmaceutical formulations, which the company identifies as its only operating segment under Ind AS 108. Its board on November 11, 2026 approved unaudited financial results for the quarter and half year end...
Bafna Pharmaceuticals Shuts Trading Window Ahead of Q2 FY27 Results
Bafna Pharmaceuticals Limited has announced the closure of its trading window for designated persons and their immediate relatives, in line with the SEBI (Prohibition of Insider Trading) Regulations and its own insider trading code. The window will b...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 07, 2026
